Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Estrogen receptor β acts as a dominant regulator of estrogen signaling

Abstract

The physiological effects of estrogens are mediated by two intracellular transcription factors, the estrogen receptors (ERs), that regulate transcription of target genes through binding to specific DNA target sequences. Here we describe alterations in cellular responses to different ER agonists and to the anti-estrogenic compound tamoxifen resulting from co-expression of the two ERs in transient co-transfection experiments. Our results demonstrate that ERβ can act as a negative or positive dominant regulator of ER activity. This is manifested through reduced transcriptional activity at low concentrations of estradiol (E2); increased antagonistic effects of tamoxifen on E2 stimulated activity; and enhanced agonistic action of the phytoestrogenic compound genistein. Furthermore, using chimeric proteins lacking the N-terminal activation function 1 (AF-1), we show that the differential responses of ERα and ERβ to different agonists and antagonists are primarily dictated by inherent differences in the C-terminal ligand-binding domains of the receptors, whereas the magnitude of transcriptional activity is influenced by ERα AF-1, but not ERβ AF-1. The ERα AF-1 activity appears to be modulated upon co-expression of both ERs. The alterations in transcriptional activity resulting from co-expression of ERα and ERβ are probably due to the formation of α/β heterodimeric complexes. This study demonstrates that co-localization and subsequent heterodimerization of ERα and ERβ may result in receptor activity distinct from that of ER homodimers.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J-Å and Nilsson S. . 1998 Mol. Pharmacol. 54: 105–112.

  • Beato M, Truss M and Chavez S. . 1996 Annal. N.Y. Acad. Sci. 784: 93–123.

  • Berry M, Metzger D and Chambon P. . 1990 EMBO J. 9: 2811–2818.

  • Chen S, Wang J, Yu G, Liu W and Pearce D. . 1997 J. Biol. Chem. 272: 14087–14092.

  • Ciocca DR and Fanelli MA. . 1997 Trends Endocrinol & Metab. 8: 313–321.

  • Cowley SM, Hoare S, Mosselman S and Parker MG. . 1997 J. Biol. Chem. 272: 19858–19862.

  • Dotzlaw H, Leygue E, Watson PH and Murphy LC. . 1999 Cancer Res. 59: 529–532.

  • Farhat MY, Lavigne MC and Ramwell PW. . 1996 FASEB J. 10: 615–624.

  • Forman BM and Evans RM. . 1995 Ann. N.Y. Acad. Sci. 761: 29–37.

  • Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H and Neyses L. . 1997 FEBS Lett. 416: 107–112.

  • Grohe C, Kahlert S, Lobbert K and Vetter H. . 1998 J. Endocrinol. 156: 1–7.

  • Gronemeyer H and Laudet V. . 1995 Prot. Profile 2: 1173–1308.

  • Hess RA, Bunick D, Lee K-H, Bahr J, Taylor JA, Korach KS and Lubahn DB. . 1997 Nature 390: 509–512.

  • Hillier SG, Saunders PT, White R and Parker MG. . 1989 J. Molec. Endocr. 2: 39–45.

  • Ingram D, Sanders K, Kolybaba M and Lopez D. . 1997 Lancet 350: 990–994.

  • Jordan VC and Morrow M. . 1999 Endocr. Rev. 20: 253–278.

  • Katzenellenbogen JA, Omalley BW and Katzenellenbogen BS. . 1996 Mol. Endocrinol. 10: 119–131.

  • Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S and Gustafson J-Å. . 1997 Endocrinology 138: 863–870.

  • Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S and Gustafsson J-Å. . 1996 Proc. Natl. Acad. Sci. USA 93: 5925–5930.

  • Kurzer MS and Xu X. . 1997 Ann. Rev. Nutr. 1997: 353–381.

  • Laudet V, Hanni C, Coll J, Catzeflis F and Stehelin D. . 1992 EMBO J. 11: 1003–1013.

  • Leygue E, Dotzlaw H, Watson PH and Murphy LC. . 1998 Cancer Res. 58: 3197–3201.

  • Li X, Schwartz PE and Rissman EF. . 1997 Neuroendocrinology 66: 63–67.

  • Lubahn DB, Moyer JS, Godling TS, Couse JF, Korach KS and Smithies O. . 1993 Proc. Natl. Acad. Sci. USA 90: 11162–11166.

  • Mangelsdorf DJ and Evans RM. . 1995 Cell 83: 841–850.

  • McInerney EM, Weis KE, Sun J, Mosselman S and Katzenellenbogen BS. . 1998 Endocrinology 139: 4513–4522.

  • Mosselman S, Polman J and Dijkema R. . 1996 FEBS Lett. 392: 49–53.

  • Perlmann T, Umesono K, Rangarajan PN, Forman BM and Evans RM. . 1996 Mol. Endocrinol. 10: 958–966.

  • Pettersson K, Grandien K, Kuiper GGJM and Gustafsson J-Å. . 1997 Mol. Endocrinol. 11: 1486–1496.

  • Saji S, Jensen EV, Nilsson S, Rylander T, Warner M and Gustafsson J-Å. . 2000 Proc. Natl. Acad. Sci. USA 97: 337–342.

  • Sasano H, Suzuki T, Matsuzaki Y, Fukaya T, Endoh M, Nagura H and Kimura M. . 1999 J. Clin. Endocrinol. & Metab. 84: 781–785.

  • Speirs V, Parkes AT, Kerin MJ, Walton DS, Carleton PJ, Fox JN and Atkin SL. . 1999 Cancer Res. 59: 525–528.

  • Trapp T, Rupprecht R, Castren M, Reul JM and Holsboer F. . 1994 Neuron 13: 1457–1462.

  • Tremblay GB, Tremblay A, Labrie F and Giguere V. . 1999 Mol. Cell. Biol. 19: 1919–1927.

  • Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F and Giguère V. . 1997 Mol. Endocrinol. 11: 353–365.

  • Tzukerman MT, Esty A, Santiso-Mere D, Danielan P, Parker MG, Stein R, Pike JW and McDonnel DP. . 1994 Mol. Endocrinol. 8: 21–30.

  • Vanacker JM, Pettersson K, Gustafsson J-Å and Laudet V. . 1999 EMBO J. 18: 4270–4279.

  • Watanabe T, Inoue S, Ogawa S, Ishii Y, Hiroi H, Ikeda K, Orimo A and Muramatsu M. . 1997 Biochem. Biophys. Res. Comm. 236: 140–145.

  • Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang S-M, Subramanian S, McInerney E, Katzenellenbogen BS, Stallcup MR and Kushner PJ. . 1998 Mol. Endocrinol. 12: 1605–1618.

Download references

Acknowledgements

This work was supported by grants from the Swedish Cancer Fund and from KaroBio AB.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pettersson, K., Delaunay, F. & Gustafsson, JÅ. Estrogen receptor β acts as a dominant regulator of estrogen signaling. Oncogene 19, 4970–4978 (2000). https://doi.org/10.1038/sj.onc.1203828

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203828

Keywords

This article is cited by

Search

Quick links